Intra-arterial reserpine for Raynaud's syndrome. Systemic reactions without therapeutic benefit.
Twenty-four patients classified as having Raynaud's disease or Raynaud's phenomenon were given bilateral brachial artery injections of reserpine or saline in a double-blind fashion. In the six weeks following injection, there was no indication that reserpine produced clinical improvement or changed vasomotor reactivity in the treated patients. However, intra-arterial reserpine did produce systemic cardiovascular effects lasting up to six weeks. It is concluded that intra-arterial reserpine as used in this study is an ineffective treatment for Raynaud's disease or Raynaud's phenomenon and may have significant adverse effects.
D000328:Adult; D001916:Brachial Artery; D002302:Cardiac Output / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007269:Injections, Intra-Arterial; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000188:drug therapy*; D012110:Reserpine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012881:Skin Temperature / Q000187:drug effects; D013318:Stroke Volume / Q000187:drug effects*
D012110:Reserpine